Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
J Vasc Surg ; 74(5): 1693-1706.e1, 2021 11.
Article in English | MEDLINE | ID: mdl-34688398

ABSTRACT

A previously published review focused on generic and disease-specific patient-reported outcome measures (PROMs) relevant to vascular surgery but limited to arterial conditions. The objective of this project was to identify all available PROMs relevant to diseases treated by vascular surgeons and to evaluate vascular surgeon perceptions, barriers to widespread implementation, and concerns regarding PROMs. We provide an overview of what a PROM is and how they are developed, and summarize currently available PROMs specific to vascular surgeons. We also report results from a survey of 78 Society for Vascular Surgery members serving on committees within the Policy and Advocacy Council addressing the barriers and facilitators to using PROMs in clinical practice. Finally, we report the qualitative results of two focus groups conducted to assess granular perceptions of PROMS and preparedness of vascular surgeons for widespread implementation of PROMs. These focus groups identified a lack of awareness of existing PROMs, knowledge of how PROMs are developed and validated, and clarity around how PROMs should be used by the clinician as main subthemes for barriers to PROM implementation in clinical practice.


Subject(s)
Endovascular Procedures , Patient Reported Outcome Measures , Peripheral Vascular Diseases/therapy , Quality of Life , Vascular Surgical Procedures , Attitude of Health Personnel , Endovascular Procedures/adverse effects , Health Knowledge, Attitudes, Practice , Humans , Patient Satisfaction , Peripheral Vascular Diseases/diagnosis , Peripheral Vascular Diseases/physiopathology , Quality Improvement , Quality Indicators, Health Care , Surgeons , Time Factors , Treatment Outcome , Vascular Surgical Procedures/adverse effects
2.
Ann Vasc Surg ; 75: 275-279, 2021 Aug.
Article in English | MEDLINE | ID: mdl-33823249

ABSTRACT

BACKGROUND: The objective of this study is to examine factors associated with thrombus extension after early experience with mechanochemical ablation, which combines mechanical damage to the venous endothelium with infusion of a sclerosant. METHODS: A retrospective review was performed of patients who underwent mechanochemical ablation to treat saphenous vein insufficiency in the thigh including the saphenofemoral junction. Data abstracted included patient demographics, procedural details, and postprocedural outcomes. Thrombus extension was determined by postprocedural duplex ultrasound and classified as flush closure with the femoral vein and any extension of thrombus into the femoral vein. RESULTS: Seventy-three patients met inclusion criteria. The mean age of the population was 60, 17.8% were female, and the mean body mass index (BMI) was 30.7. Seven (9.6%) patients who underwent mechanochemical ablation experienced saphenous vein closure flush with the femoral vein. Eleven (15%) patients experience extension of thrombus to less than 50% of the diameter of the femoral vein and one patient experienced complete thrombosis of the femoral vein. There was no significant difference in age, sex, or comprehensive classification system for chronic venous disorders between the group with thrombus extension and the group without, with the exception of BMI. The mean BMI in the group with thrombus extension was 26.8 vs. 32 in the group without (P = 0.02). There was no significant difference between the 2 groups in sclerosant volume used, distance between catheter tip and SFJ, and mean diameter of GSV in the thigh. CONCLUSIONS: In this cohort, the incidence of thrombus extension into the femoral vein with mechanochemical ablation was high relative to rates of thrombus extension associated with reported rates of thermal ablation. Further investigation with larger cohorts, and standardized reporting is required to characterize the true rate of thrombus extension after mechanochemical ablation and identify maneuvers which may prevent thrombus extension.


Subject(s)
Femoral Vein , Radiofrequency Ablation/adverse effects , Saphenous Vein/surgery , Sclerosing Solutions/adverse effects , Sclerotherapy/adverse effects , Thrombosis/etiology , Venous Insufficiency/therapy , Combined Modality Therapy , Female , Femoral Vein/diagnostic imaging , Humans , Infusions, Intravenous , Male , Middle Aged , Retrospective Studies , Saphenous Vein/diagnostic imaging , Sclerosing Solutions/administration & dosage , Thrombosis/diagnostic imaging , Time Factors , Treatment Outcome , Venous Insufficiency/diagnostic imaging
3.
Am J Physiol Heart Circ Physiol ; 316(2): H421-H429, 2019 02 01.
Article in English | MEDLINE | ID: mdl-30499713

ABSTRACT

The heat shock response is an important cytoprotective mechanism for protein homeostasis and is an essential protective response to cellular stress and injury. Studies on changes in the heat shock response with aging have been mixed with regard to whether it is inhibited, and this, at least in part, reflects different tissues and different models. Cellular senescence is a key feature in aging, but work on the heat shock response in cultured senescent (SEN) cells has largely been limited to fibroblasts. Given the prevalence of oxidative injury in the aging cardiovascular system, we investigated whether SEN primary human coronary artery endothelial cells have a diminished heat shock response and impaired proteostasis. In addition, we tested whether this downregulation of heat shock response can be mitigated by 17ß-estradiol (E2), which has a critical cardioprotective role in women, as we have previously reported that E2 improves the heat shock response in endothelial cells (Hamilton KL, Mbai FN, Gupta S, Knowlton AA. Arterioscler Thromb Vasc Biol 24: 1628-1633, 2004). We found that SEN endothelial cells, despite their unexpectedly increased proteasome activity, had a diminished heat shock response and had more protein aggregation than early passage cells. SEN cells had increased oxidative stress, which promoted protein aggregation. E2 treatment did not decrease protein aggregation or improve the heat shock response in either early passage or SEN cells. In summary, cellular senescence in adult human endothelial cells is accompanied by increased oxidative stress and a blunting of proteostasis, and E2 did not mitigate these changes. NEW & NOTEWORTHY Senescent human endothelial cells have a diminished heat shock response and increased protein aggregates. Senescent human endothelial cells have increased basal oxidative stress, which increases protein aggregates. Physiological level of 17ß-estradiol did not improve proteostasis in endothelial cells.


Subject(s)
Cellular Senescence , Endothelial Cells/metabolism , Endothelium, Vascular/growth & development , Estradiol/pharmacology , Estrogens/pharmacology , Oxidative Stress , Proteostasis , Adolescent , Adult , Cells, Cultured , Endothelial Cells/drug effects , Endothelial Cells/physiology , Endothelium, Vascular/metabolism , Female , Heat-Shock Response , Humans , Middle Aged
4.
PLoS One ; 13(1): e0190374, 2018.
Article in English | MEDLINE | ID: mdl-29315311

ABSTRACT

NEW AND NOTEWORTHY: Previously, quercetin has been reported to be a senolytic, a drug that selectively removes senescent cells, in HUVECs. However, we found neither quercetin nor Q3G was effective as a senolytic for adult human endothelial cells.


Subject(s)
Cellular Senescence/drug effects , Endothelium, Vascular/drug effects , Quercetin/analogs & derivatives , Quercetin/pharmacology , Adult , Cell Proliferation/drug effects , Endothelium, Vascular/cytology , Female , Human Umbilical Vein Endothelial Cells , Humans
SELECTION OF CITATIONS
SEARCH DETAIL